These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 26476076)

  • 1. Pharmacological Targeting SHP-1-STAT3 Signaling Is a Promising Therapeutic Approach for the Treatment of Colorectal Cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Neoplasia; 2015 Sep; 17(9):687-696. PubMed ID: 26476076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP-1 is a target of regorafenib in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Lin H; Hung MH; Chen YL; Huang JW; Tai WT; Yu HC; Chen KF
    Oncotarget; 2014 Aug; 5(15):6243-51. PubMed ID: 25071018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obatoclax analog SC-2001 inhibits STAT3 phosphorylation through enhancing SHP-1 expression and induces apoptosis in human breast cancer cells.
    Liu CY; Su JC; Ni MH; Tseng LM; Chu PY; Wang DS; Tai WT; Kao YP; Hung MH; Shiau CW; Chen KF
    Breast Cancer Res Treat; 2014 Jul; 146(1):71-84. PubMed ID: 24903225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma.
    Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF
    Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential combination of docetaxel with a SHP-1 agonist enhanced suppression of p-STAT3 signaling and apoptosis in triple negative breast cancer cells.
    Liu CY; Chen KF; Chao TI; Chu PY; Huang CT; Huang TT; Yang HP; Wang WL; Lee CH; Lau KY; Tsai WC; Su JC; Wu CY; Chen MH; Shiau CW; Tseng LM
    J Mol Med (Berl); 2017 Sep; 95(9):965-975. PubMed ID: 28578456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disrupting VEGF-A paracrine and autocrine loops by targeting SHP-1 suppresses triple negative breast cancer metastasis.
    Su JC; Mar AC; Wu SH; Tai WT; Chu PY; Wu CY; Tseng LM; Lee TC; Chen KF; Liu CY; Chiu HC; Shiau CW
    Sci Rep; 2016 Jul; 6():28888. PubMed ID: 27364975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
    Liu CY; Su JC; Huang TT; Chu PY; Huang CT; Wang WL; Lee CH; Lau KY; Tsai WC; Yang HP; Shiau CW; Tseng LM; Chen KF
    Mol Oncol; 2017 Mar; 11(3):266-279. PubMed ID: 28084011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma.
    Fan LC; Shiau CW; Tai WT; Hung MH; Chu PY; Hsieh FS; Lin H; Yu HC; Chen KF
    Oncogene; 2015 Oct; 34(41):5252-63. PubMed ID: 25619838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A sorafenib derivative and novel SHP-1 agonist, SC-59, acts synergistically with radiotherapy in hepatocellular carcinoma cells through inhibition of STAT3.
    Huang CY; Tai WT; Hsieh CY; Hsu WM; Lai YJ; Chen LJ; Shiau CW; Chen KF
    Cancer Lett; 2014 Jul; 349(2):136-43. PubMed ID: 24735751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
    Wang CY; Chao TT; Tai WT; Chang FY; Su WP; Chen YL; Chen PT; Weng CY; Yuan A; Shiau CW; Yu CJ; Chen KF
    J Thorac Oncol; 2014 Apr; 9(4):488-96. PubMed ID: 24736071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
    Liu CY; Tseng LM; Su JC; Chang KC; Chu PY; Tai WT; Shiau CW; Chen KF
    Breast Cancer Res; 2013; 15(4):R63. PubMed ID: 23938089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
    Tai WT; Shiau CW; Chen PJ; Chu PY; Huang HP; Liu CY; Huang JW; Chen KF
    Hepatology; 2014 Jan; 59(1):190-201. PubMed ID: 23908138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phloretin attenuates STAT-3 activity and overcomes sorafenib resistance targeting SHP-1-mediated inhibition of STAT3 and Akt/VEGFR2 pathway in hepatocellular carcinoma.
    Saraswati S; Alhaider A; Abdelgadir AM; Tanwer P; Korashy HM
    Cell Commun Signal; 2019 Oct; 17(1):127. PubMed ID: 31619257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
    Tai WT; Shiau CW; Li YS; Chen YL; Chu PY; Huang JW; Hsu CY; Hsu YC; Chen PJ; Chen KF
    Mol Cancer Ther; 2014 Jan; 13(1):27-36. PubMed ID: 24275147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel obatoclax derivative, SC-2001, induces apoptosis in hepatocellular carcinoma cells through SHP-1-dependent STAT3 inactivation.
    Chen KF; Su JC; Liu CY; Huang JW; Chen KC; Chen WL; Tai WT; Shiau CW
    Cancer Lett; 2012 Aug; 321(1):27-35. PubMed ID: 22465052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Src-homology protein tyrosine phosphatase-1 agonist, SC-43, reduces liver fibrosis.
    Su TH; Shiau CW; Jao P; Yang NJ; Tai WT; Liu CJ; Tseng TC; Yang HC; Liu CH; Huang KW; Hu TC; Huang YJ; Wu YM; Chen LJ; Chen PJ; Chen DS; Chen KF; Kao JH
    Sci Rep; 2017 May; 7(1):1728. PubMed ID: 28496142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
    Su JC; Chiang HC; Tseng PH; Tai WT; Hsu CY; Li YS; Huang JW; Ko CH; Lin MW; Chu PY; Liu CY; Chen KF; Shiau CW
    Carcinogenesis; 2014 Dec; 35(12):2807-14. PubMed ID: 25322871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.
    Liu CY; Huang TT; Chu PY; Huang CT; Lee CH; Wang WL; Lau KY; Tsai WC; Chao TI; Su JC; Chen MH; Shiau CW; Tseng LM; Chen KF
    Exp Mol Med; 2017 Aug; 49(8):e366. PubMed ID: 28798401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.